Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 3Carcinoma, Squamous Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neoplasm Metastasis 1Mycosis Fungoides 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Carcinoma, Merkel Cell 1Breast Carcinoma In Situ 1

Interventions

Capecitabine 35Oxaliplatin 32Fluorouracil 29Leucovorin 26Irinotecan 22Bevacizumab 19Cetuximab 17Radiotherapy 16Radiation 11Surgical Procedures, Operative 6Radiotherapy, Intensity-Modulated 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5Celecoxib 5Neoadjuvant Therapy 4Immunohistochemistry 4Biopsy 4Amplified Fragment Length Polymorphism Analysis 4cediranib 3Reverse Transcriptase Polymerase Chain Reaction 3Receptor Protein-Tyrosine Kinases 3Folfox protocol 3Drug Therapy 3Cisplatin 3sargramostim 2regorafenib 2pembrolizumab 2fludarabine phosphate 2aldesleukin 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rectal Neoplasms × talimogene laherparepvec × Clear all
NCT03300544 2024-05-23

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
3 enrolled 9 charts
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡